GeneDx Holdings Corp. stocks have been trading up by 8.08 percent following upbeat coverage of its genetic testing advances.
Click Here for a Millionaire's POV on Trading WGS
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q1 2026 revenue rose 17% year over year to $102.3M, with 34% test volume growth and a strong 69% adjusted gross margin, but WGS still posted an $8.2M adjusted net loss and a large GAAP loss.
- Management slashed 2026 revenue guidance from $540–$555M to $475–$490M on weaker pricing and volumes, yet still targets about 70% gross margin, over 30% volume growth, and positive adjusted net income.
- Wall Street cut WGS price targets sharply after the miss and guidance reset, but TD Cowen, Guggenheim, BTIG, Canaccord, and Wells Fargo all kept Buy or Overweight ratings.
- A major insider, Keith A. Meister, bought 1,205,147 WGS shares for roughly $46.8M, while ARK Investment added 246,000 shares, signaling notable insider and institutional support.
- GeneDx guided Q2 2026 revenue to $110M–$112M, offering solid sequential growth and a key near-term checkpoint for WGS traders watching for stabilization.
Live Update At 14:02:52 EDT: On Friday, May 15, 2026 GeneDx Holdings Corp. stock [NASDAQ: WGS] is trending up by 8.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
For traders, GeneDx Holdings Corp. is turning into a classic high‑growth, high‑volatility story. On the P&L, WGS delivered $102.3M in Q1 2026 revenue, up 17% from a year earlier, with exome and genome testing volumes jumping 34%. Gross margin near 69% shows the core lab business is structurally profitable at the unit level. The problem is everything below that line.
Operating expenses of roughly $94M drove an operating loss of about $57M and a net loss of $63.3M, helped by a sizable goodwill and intangibles impairment. Key ratios back this up: return on assets and equity are deeply negative, and free cash flow was about -$38.9M for the quarter. WGS is still paying to grow.
On the balance sheet, GeneDx holds around $94.9M in cash, current assets of $270.6M, and a current ratio of 2.5, which gives the company breathing room. Long‑term debt of about $96.7M and total liabilities of $252.2M are manageable relative to a $548.1M enterprise value, but weak interest coverage highlights the need to reach profitability.
More Breaking News
- Atlassian TEAM Stock Surges As AI Momentum Ignites
- BBAI Stock Steadies As BigBear.ai Builds Defense AI Momentum
- BMNR Stock Magnetizes Traders With Giant Ethereum Bet
- QUBT Stock Jumps As Earnings Beat Fuels Quantum Momentum
The chart tells you traders are already pricing in that tension. WGS has slid from the high-$60s in late April 2026 to the low-$40s by 2026/05/15. That is a heavy repricing. Yet intraday action on 2026/05/15 shows a grind higher from about $38 to nearly $42, with steady higher lows through the session. That intraday trend suggests dip‑buyers are probing for a short‑term floor after the news shock.
Why Traders Are Watching WGS After The Reset
The whole WGS story right now is about a painful reset colliding with still‑strong operating momentum. GeneDx told the market Q1 2026 revenue came in at $102.3M versus Street expectations of $112.45M. Management then cut full‑year revenue guidance by roughly $65M at the midpoint, from $540–$555M down to $475–$490M. For a high‑growth genomics name, that kind of guide‑down will always sting, and the chart confirms traders hit the sell button.
The mechanics behind the miss matter. GeneDx is seeing a rapid mix shift from higher‑priced whole exome sequencing (WES) to lower‑priced whole genome sequencing (WGS). Volumes are booming — exome/genome revenue grew 27%, tests grew 34% — but average selling prices are under pressure, and non‑core data and software revenue is softer. So traders looking at WGS need to separate volume momentum from revenue per test.
Wall Street has already done that math. TD Cowen cut its GeneDx price target to $55 from $60, Guggenheim dropped to $70 from $100, BTIG to $90 from $170, Canaccord to $75 from $100, and Wells Fargo to $75 from $155. Those are big target cuts. Yet every one of these firms kept a Buy or Overweight rating on WGS.
Their argument is simple: guidance has been de‑risked, exome/genome volumes remain strong, and management still expects more than 30% volume growth, about 70% gross margin, and positive adjusted net income for 2026. On top of that, GeneDx guided Q2 revenue to $110M–$112M, implying sequential growth despite the reset. For active traders, those numbers create a clear roadmap of catalysts and checkpoints over the next few quarters.
Ownership moves add another twist. A fresh Schedule 13D shows a significant shareholder adjusting its stake, and director Keith A. Meister just bought 1,205,147 WGS shares for around $46.8M, raising his holdings to 4,786,570 shares. ARK Investment also picked up 246,000 GeneDx shares. When you see both a major insider and a high‑profile fund leaning in after bad news, you know this is a battleground name to keep on the radar.
Conclusion
WGS now sits at a crossroads that experienced traders know well. On one side, GeneDx has high growth, expanding clinical adoption, and payer wins like broader Medicaid coverage. Q1 2026 showed 17% revenue growth, 34% test volume growth, and gross margins near 70%. Those are not the numbers of a broken business. On the other side, you have a sharp 2026 guidance cut, a big GAAP loss with impairment, and ongoing cash burn.
The market’s first reaction was to hammer the stock from the upper-$60s toward the $40 area. That move makes sense when traders reprice a story for lower revenue and higher perceived risk. But as the dust settles, the question for short‑term and swing traders is whether WGS now trades more on fear than on fundamentals. As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” For many pattern‑recognition‑focused traders, that mindset is exactly what keeps them tracking a volatile name like this rather than walking away after the first big move.
Ongoing insider and institutional buying is one reason this ticker remains front and center. Meister’s $46.8M purchase and ARK’s 246,000‑share addition signal real money sees value in GeneDx at these levels, even with near‑term volatility. At the same time, every major covering firm cut its price target yet stayed positive on WGS’s multi‑year outlook, betting that mix, pricing, and reimbursement on whole genome sequencing normalize over time.
For traders studying this setup, the plan is not about predicting the future. It is about reacting to price action around clear catalysts — Q2 results versus that $110M–$112M guide, any updates to margins, and further insider or 13D moves. As Tim Sykes likes to say, “Discipline and risk management are the real edges in trading.” With a name like GeneDx Holdings Corp., where the story is hot and the numbers are swinging, that mindset matters more than ever. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.